Showing results (1-10 of 242) with videos related to
Sort By:
Pageof 25
Seminars in Nuclear Medicine|December 19, 2016
Imaging in Central Nervous System Drug DiscoveryRoger N Gunn, Eugenii A RabinerJournal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|November 9, 2023
Estimation of target occupancy in repeated dosing design studies using positron emission tomography: Biases due to target upregulationEugenii A Rabiner, Roger N GunnBritish Journal of Clinical Pharmacology|August 16, 2011
Positron emission tomography molecular imaging for drug developmentPaul M Matthews, Eugenii A Rabiner, Jan Passchier, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 10, 2009
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visitedVincent J Cunningham, Eugenii A Rabiner, Mark Slifstein, et al.Neuroimage|January 19, 2012
Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivoQi Guo, David R Owen, Eugenii A Rabiner, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 17, 2014
A graphical method to compare the in vivo binding potential of PET radioligands in the absence of a reference region: application to [¹¹C]PBR28 and [¹⁸F]PBR111 for TSPO imagingQi Guo, David R Owen, Eugenii A Rabiner, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 6, 2004
Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression?Eugenii A Rabiner, Zubin Bhagwagar, Roger N Gunn, et al.Journal of Psychopharmacology (Oxford, England)|September 19, 2002
Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]racloprideEugenii A Rabiner, Roger N Gunn, Martin R Wilkins, et al.Drug Discovery Today. Technologies|July 2, 2014
PET studies in drug development: Methodological considerationsVincent J Cunningham, Christine A Parker, Eugenii A Rabiner, et al.Journal of Psychopharmacology (Oxford, England)|June 27, 2007
Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?Eugenii A RabinerPageof 25